Inclusion Criteria:

- Histologically or cytologically proven small cell lung cancer

- Patients currently receiving 4-6 cycles of chemotherapy regimen with VP-16 and a
platinum-based drug as first-line therapy in the absence of disease progression

- Age between 18-75

- Performance status ≤2

- No uncontrolled metabolic disease, infection, and neurological disorders

- No congestive heart failure, severe arrhythmia, and coronal atherosclerosis heart
disease

- Life expectancy more than three months.

- Without contraindication of immunotherapy with autologous cytokine-induced killer
cells

- No other malignancies

- Signed study-specific consent form prior to study entry

Exclusion Criteria:

- Patients receiving other anti-tumor therapy (like thermotherapy)

- Pregnant or lactating women

- Allergy or unacceptable toxicity of immunotherapy with autologous cytokine-induced
killer cells

- Uncontrolled mental disorder

- Patient having acute hepatitis virus infection, active tuberculosis, or other acute
infectious diseases